Epigallocatechin gallate (egcg) attenuates severe acute respiratory coronavirus disease 2 (sars-cov-2) infection by blocking the interaction of sars-cov-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2

HIGHLIGHTS

• who: Tomokazu Ohishi and colleagues from the Editor: Luis M Schang, Cornell University, UNITED , Tea Solutions, Hara Office Inc, Sumida-ku, Tokyo, Japan have published the paper: Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2, in the Journal: PLOS ONE of 18/07/2021
• what: The authors selected many common phytochemicals found in various plants, based on evidences showing their potential bioactivities for treating several diseases, such as rheumatoid arthritis . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.